Journal of veterinary pharmacology and therapeutics2013; 37(4); 413-416; doi: 10.1111/jvp.12097

Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses.

Abstract: Simultaneous administration of a nonselective COX inhibitor and a COX-2 specific NSAID has not been previously reported in horses. The goal of this study was to determine the safety of a 10-day dosage regimen of phenylbutazone and firocoxib, both at their standard dosages, in horses. Six horses were administered 2.2 mg/kg of phenylbutazone and 0.1 mg/kg of firocoxib by mouth, daily for 10 days. Horses were assessed daily for changes in behavior, appetite, fecal consistency, signs of abdominal pain, and oral mucous membrane ulceration. Horses were assessed prior to and on the last day of treatment for changes in serum creatinine, albumin, total protein, and urine-specific gravity. Horses underwent endoscopic examination of the esophagus, stomach, and pylorus prior to and 24 hours after the last treatment. A significant change in serum creatinine and total protein was observed on day 10 of treatment. No other significant findings were noted during the experiment. Results indicated that co-administration of phenylbutazone and firocoxib may cause renal disease.
Publication Date: 2013-12-20 PubMed ID: 24354928DOI: 10.1111/jvp.12097Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigated the combination of two different drugs, phenylbutazone and firocoxib, in horses, and found that the co-administration of these drugs for ten days could potentially lead to renal disease.

Objective of the Research

The research was primarily aimed at testing the impact of administering two different drugs, phenylbutazone and firocoxib together to horses over a ten day period. There were no previous records of this combination being tested together in horses, hence this study is pioneering that field. Phenylbutazone is a non-selective COX inhibitor, while firocoxib is a COX-2 specific NSAID.

  • Horses were assessed daily for changes in behavior, appetite, fecal consistency, signs of abdominal pain, and oral mucous membrane ulceration.
  • They also performed tests on the horses for changes in serum creatinine, albumin, total protein, and urine-specific gravity before and after the treatment.
  • Moreover, endoscopic examination of the esophagus, stomach, and pylorus was carried out before and after the treatment.

Findings of the Study

Results drawn from the study were reasonably clear and led to one important finding.

  • There was a significant increase in serum creatinine and total protein on the 10th day of treatment.
  • No significant changes were noted in behavior, appetite, fecal consistency, signs of abdominal pain, and oral mucous membrane ulceration.
  • Also, no notable changes were found in albumin and urine-specific gravity levels.
  • Endoscopic studies of the esophagus, stomach, and pylorus also didn’t show any notable changes.

Conclusion of the Study

This study concluded that the combination of the drugs phenylbutazone and firocoxib administration for ten days could potentially lead to renal diseases in horses. Hence caution might be necessary while co-administering these drugs, as the significant increase in serum creatinine and total protein could indicate damage to the kidneys. However, the study didn’t note other significant impacts in the horses that were part of this research.

Cite This Article

APA
Kivett L, Taintor J, Wright J. (2013). Evaluation of the safety of a combination of oral administration of phenylbutazone and firocoxib in horses. J Vet Pharmacol Ther, 37(4), 413-416. https://doi.org/10.1111/jvp.12097

Publication

ISSN: 1365-2885
NlmUniqueID: 7910920
Country: England
Language: English
Volume: 37
Issue: 4
Pages: 413-416

Researcher Affiliations

Kivett, L
  • Foundation Equine Mobile Medicine and Dentistry, Southern Pines, NC, USA.
Taintor, J
    Wright, J

      MeSH Terms

      • 4-Butyrolactone / administration & dosage
      • 4-Butyrolactone / adverse effects
      • 4-Butyrolactone / analogs & derivatives
      • Administration, Oral
      • Animals
      • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
      • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
      • Blood Proteins
      • Creatinine / blood
      • Drug Therapy, Combination
      • Horse Diseases / blood
      • Horse Diseases / chemically induced
      • Horses
      • Kidney Diseases / chemically induced
      • Kidney Diseases / veterinary
      • Phenylbutazone / administration & dosage
      • Phenylbutazone / adverse effects
      • Prostaglandin-Endoperoxide Synthases / metabolism
      • Sulfones / administration & dosage
      • Sulfones / adverse effects

      Citations

      This article has been cited 7 times.
      1. Mercer MA, Davis JL, McKenzie HC. The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses.. Animals (Basel) 2023 May 10;13(10).
        doi: 10.3390/ani13101597pubmed: 37238029google scholar: lookup
      2. Mercer MA, Davis JL, McKenzie HC, Messenger KM, Schaefer E, Council-Troche RM, Werre SR. Pharmacokinetics and efficacy of orallyu00a0administered acetaminophen (paracetamol) in adult horses with experimentally induced endotoxemia.. J Vet Intern Med 2023 Mar;37(2):718-727.
        doi: 10.1111/jvim.16663pubmed: 36840424google scholar: lookup
      3. Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses.. Vet Anim Sci 2023 Mar;19:100286.
        doi: 10.1016/j.vas.2023.100286pubmed: 36684818google scholar: lookup
      4. Flood J, Stewart AJ. Non-Steroidal Anti-Inflammatory Drugs and Associated Toxicities in Horses.. Animals (Basel) 2022 Oct 26;12(21).
        doi: 10.3390/ani12212939pubmed: 36359062google scholar: lookup
      5. Donnell JR, Frisbie DD. Use of firocoxib for the treatment of equine osteoarthritis.. Vet Med (Auckl) 2014;5:159-168.
        doi: 10.2147/VMRR.S70207pubmed: 32670856google scholar: lookup
      6. Tesena P, Yingchutrakul Y, Roytrakul S, Wongtawan T, Angkanaporn K. Serum protein expression in Equine Glandular Gastric Disease (EGGD) induced by phenylbutazone.. J Vet Med Sci 2019 Mar 20;81(3):418-424.
        doi: 10.1292/jvms.18-0679pubmed: 30674748google scholar: lookup
      7. Ziegler A, Fogle C, Blikslager A. Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses.. J Am Vet Med Assoc 2017 Jun 1;250(11):1271-1274.
        doi: 10.2460/javma.250.11.1271pubmed: 28509650google scholar: lookup